Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2004

View Archived Issues

Merck researchers claim new tyrosine kinase regulators and their use

Novel 5-HT receptor ligands with utility in psychotic conditions

New glucokinase activators emerge from Roche R&D

Pfizer scientists design novel cannabinoid CB1 antagonists for obesity and alcohol and tobacco abuse

Novel dopamine D3 agonists and their use in sexual disorders

Novartis presents new VEGF inhibitors for cancer and ocular disorders

Novel propapoptotic agents newly developed at Aponetics

HIV-1 integrase inhibitor promising against resistant viral strains

Nonnucleoside adenosine deaminase inhibitor shows antiinflammatory activity in vivo

Promising nonpeptide BACE inhibitor decreases the formation of amyloid plaques in vivo

Approval for new liquid formulation of Synagis

Enrollment completed in STELLAR 2 trial of Xyotax

Celera Genomics receives cathepsin K milestone from Merck

APD-356 enters phase Ib study for obesity

Boston Life Sciences files IND for phase I study of Axosine

Enrollment completed in phase I/II study of GA-GCB for Gaucher's disease

Abbott seeks approval of once-daily Kaletra in U.S., E.U.

KOS-862 enters phase Ib trial in combination with Paraplatin for solid tumors

New phase II study of Titan's DITPA for CHF

Y's Therapeutics files in begin European phase II studies of YS-IL6 and YS-TH2

Combination regimens in the treatment of CTCL

Phase Ib study of TACI-Ig in SLE

Survival benefits of Canvaxin in metastatic melanoma

Locus and P&G collaborate on diabetes drug design

Phase I trial of ON-01910Na commences enrollment

Agensys enters collaboration and license agreement with Genentech

Phase II study of Theratope for metastatic breast cancer completes enrollment

Clinical study cleared to begin of HGF plasmid for ischemic heart disease